Summary
The resurgence of pertussis (whooping cough) becomes a serious problem in many countries including the UK. Differentiation of the accumulated monthly numbers of pertussis cases registered in England in 2023 and 2024 revealed two waves of the epidemic before and after October 2023. Identification of parameters of SIR (susceptible-infectious-removed) model allowed calculating the numbers of infectious persons and reproduction rates. The accumulated and daily numbers of cases and the duration of the first wave were predicted. If the influence of second wave will be not very significant, the new cases will stop to appear in the end of August 2025 after reaching the figure of 5.8 thousand. The maximum of average daily numbers of new cases is expected to be around 51 on 9-10 May 2024. Since the effective reproduction number is very close to its critical value 1.0, the probably of new outbreaks is very high. May be the, increase of percentage of vaccinated people could decrease this probability.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
INI-LMS Solidarity Programme at the University of Warwick, UK
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
